I-MED Pharma Inc., a Canadian-based firm, announced this week the expansion of its strategic partnership with ESW Vision in France to be their exclusive distributor in the United States.
Montreal-based I-MED Pharma Inc. announced this week the expansion of its strategic partnership with ESW Vision in France to be their exclusive distributor in the United States.
Through I-MED Pharma USA, two dry eye devices will be available directly to all eye care professionals across the country.
E>Eye, is the first and only CE certified medical device in the world using patented IRPL technology developed specifically for the treatment of dry eye disease caused by meibomian gland dysfunction (MGD), the leading cause of evaporative dry eye.
According to the company, this form of polychromatic pulsed light produces calibrated and homogeneously sequenced “cold light” pulses which safely stimulate the meibomian glands to resume secretions, restoring the lacrymal film and improving symptoms associated with ocular dryness.
Tearcheck is a dry eye diagnostic and analyzer tool that performs nine exams in under ten minutes. The innovative technology and unique usability of this diagnostic device creates a new standard for dry eye analysis.
According to Philipp Binder, president and COO of I-MED Pharma, the company is proud to be building on the worldwide success of these dry eye devices.
“With thousands of units installed worldwide, this technology has become globally regarded as the gold standard,” he said in a statement. These devices have been quickly recognized as the number one technology in Canada by eye care professionals, and we are excited to bring this innovation to the US market. Our strategic collaboration with ESW Vision over the last three years has pushed us forward in our mission to bring complete relief to dry eye and ocular surface disease patients worldwide.”
I-MED Pharma USA is a subsidiary of I-MED Pharma Inc., a privately held Canadian company, headquartered in Montreal, Quebec.